Pre-Effective Amendment to Registration of Securities Issued in a Business-Combination Transaction — Form S-4
Filing Table of Contents
Document/Exhibit Description Pages Size
1: S-4/A Amendement No.1 to Form S-4 189 1.10M
2: EX-2.2 Agreement, Dated as of July 7, 1995 7 25K
3: EX-2.3 Agreement, Dated as of September 6, 1995 12 40K
4: EX-5.1 Opinion of Wachtell, Lipton, Rosen 2 10K
5: EX-8.1 Opinion of Wachtell, Lipton, Rosen 1 9K
6: EX-10.4 Agency Agreement, Dated as of September 6, 1995 12 39K
7: EX-10.5 Letter Agreement, Dated September 6, 1995 2 12K
8: EX-15.1 Letter Re: Unaudited Interim Financial Information 1 8K
9: EX-23.2 Consent of Ernst & Young LLP 1 8K
10: EX-23.3 Consent of Price Waterhouse Ag 1 6K
11: EX-24.1 Powers of Attorneys 1 9K
12: EX-27.1 Financial Data Schedule 1 10K
13: EX-99.1 Form of Proxy for Special Meeting of Stockholders 2± 11K
EX-23.3 — Consent of Price Waterhouse Ag
EX-23.3 | TOC | ↑Top | Previous | Next | ↓Bottom | Just 1st |
---|
Exhibit 23.3
Consent of Roche Group Auditors
We hereby consent to the use in the Proxy Statement/Prospectus of Genentech Inc.
of our report dated 27 April 1995 which appears in such Proxy Statement/
Prospectus and relates to the consolidated financial statements of the Roche
Group which have been extracted from the 1994 Annual Report. We also consent
to the reference to us under the heading "Experts" in such Proxy Statement/
Prospectus.
Price Waterhouse AG
Jack W. Flamson Ralph R. Reinertsen
Certified Public Accountant Certified Public Accountant
Auditors in charge
Basel, Switzerland
7 September 1995
↑Top
Filing Submission 0000950123-95-002577 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Tue., May 14, 12:07:15.1am ET